This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaltsas, G. Articles by Grossman, A. B. Search for Related Content PubMed PubMed Citation Articles by Kaltsas, G. Articles by Grossman, A. B.

Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors

Departments of Endocrinology (G.K., M.K., E.Z., J.J.M., P.J.J., S.L.C., J.P.M., G.M.B., A.B.G.), Diagnostic Radiology (R.R.), and Nuclear Medicine (R.F., K.E.B.), St. Bartholomew’s Hospital, London, United Kingdom EC1A 7BE

Address all correspondence and requests for reprints to: Prof. A. B. Grossman, Department of Endocrinology, St. Bartholomew’s Hospital, London, United Kingdom ECIA 7BE. E-mail: a.b.grossman{at}mds.qmw.ac.uk

A comparison has been made of [¹²³I]meta-iodobenzylguanidine ([¹²³I]MIBG) and [¹¹¹In]pentetreotide scintigraphy in 54 patients with a variety of neuroendocrine tumors of whom 46 patients had metastatic disease. [¹¹¹In]Pentetreotide scintigraphy was more sensitive in detecting metastatic lesions, as demonstrated on computed tomography and/or magnetic resonance scanning, than [¹²³I]MIBG: 67% vs. 50% for carcinoid tumors (n = 24), 91% vs. 9% for pancreatic islet cell tumors (n = 12), 100% vs. 60% for medullary thyroid carcinomas (n = 5), and 75% vs. 100% for pheochromocytomas/paragangliomas (n = 4). In only 2 patients were lesions seen with [¹²³I]MIBG scanning that were not apparent with [¹¹¹In]pentetreotide. With the exception of pancreatic islet cell tumors, both radionuclides exhibited a similar sensitivity in detecting hepatic metastases, whereas in three patients the two radionuclides exerted a complementary role as different deposits exhibited uptake to only 1 or the other radionuclide. Hepatic metastases were the most important clinical predictor of a positive scan for both radionuclides. Neither elevated 5-hydroxyindoleacetic acid levels nor any other hormonal marker was predictive of a positive scan. In 8 patients with clinical and/or hormonal evidence of a neuroendocrine tumor but negative conventional radiology, [¹¹¹In]pentetreotide scintigraphy was more sensitive than [¹²³I]MIBG (37.5% vs. 12.5%) in detecting lesions.

In conclusion, scintigraphy with [¹¹¹In]pentetreotide detects more metastatic lesions than [¹²³I]MIBG in patients with carcinoid and pancreatic islet cell tumors and medullary thyroid carcinomas; [¹²³I]MIBG scintigraphy may be more sensitive for sympathoadrenomedullary tumors. The radionuclides may exert a complementary role in the detection and treatment of neuroendocrine tumors in occasional patients, as areas of different pattern of uptake were identified within the same patient. These data have implications not only for staging such tumors, but also for identifying patients who might benefit from treatment using either [¹³¹I]MIBG or radioactive somatostatin analogs.

This article has been cited by other articles:

				D. Pasquali, V. Rossi, G. Conzo, G. Pannone, P. Bufo, A. De Bellis, A. Renzullo, G. Bellastella, A. Colao, G. Vallone, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells J. Mol. Endocrinol., June 1, 2008; 40(6): 263 - 271. [Abstract] [Full Text] [PDF]

				M. H Kulke Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr. Relat. Cancer, June 1, 2007; 14(2): 207 - 219. [Abstract] [Full Text] [PDF]

				T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert Current Treatment of Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225. [Abstract] [Full Text] [PDF]

				A. F. Scarsbrook, A. Ganeshan, J. Statham, R. V. Thakker, A. Weaver, D. Talbot, P. Boardman, K. M. Bradley, F. V. Gleeson, and R. R. Phillips Anatomic and Functional Imaging of Metastatic Carcinoid Tumors RadioGraphics, March 1, 2007; 27(2): 455 - 477. [Abstract] [Full Text] [PDF]

				E. ZAPANTI and I. ILIAS Pheochromocytoma: Physiopathologic Implications and Diagnostic Evaluation Ann. N.Y. Acad. Sci., November 1, 2006; 1088(1): 346 - 360. [Abstract] [Full Text] [PDF]

				A. GROSSMAN, K. PACAK, A. SAWKA, J. W. M LENDERS, D. HARLANDER, R. T PEASTON, R. REZNEK, J. SISSON, and G. EISENHOFER Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 332 - 347. [Abstract] [Full Text] [PDF]

				H. AHLMAN Malignant pheochromocytoma: state of the field with future projections. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 449 - 464. [Abstract] [Full Text] [PDF]

				M. T. Madsen, D. L. Bushnell, M. E. Juweid, Y. Menda, M. S. O'Dorisio, T. O'Dorisio, and I. M. Besse Potential Increased Tumor-Dose Delivery with Combined 131I-MIBG and 90Y-DOTATOC Treatment in Neuroendocrine Tumors: A Theoretic Model J. Nucl. Med., April 1, 2006; 47(4): 660 - 667. [Abstract] [Full Text] [PDF]

				S. Ezziddin, T. Logvinski, C. Yong-Hing, H. Ahmadzadehfar, H.-P. Fischer, H. Palmedo, J. Bucerius, M. J. Reinhardt, and H.-J. Biersack Factors Predicting Tracer Uptake in Somatostatin Receptor and MIBG Scintigraphy of Metastatic Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., February 1, 2006; 47(2): 223 - 233. [Abstract] [Full Text] [PDF]

				J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Gut, June 1, 2005; 54(suppl_4): iv1 - iv16. [Full Text] [PDF]

				D. Vezzosi, A. Bennet, P. Rochaix, F. Courbon, J. Selves, B. Pradere, L. Buscail, C. Susini, and P. Caron Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies Eur. J. Endocrinol., May 1, 2005; 152(5): 757 - 767. [Abstract] [Full Text] [PDF]

				K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				I. ILIAS and K. PACAK Anatomical and Functional Imaging of Metastatic Pheochromocytoma Ann. N.Y. Acad. Sci., June 1, 2004; 1018(1): 495 - 504. [Abstract] [Full Text] [PDF]

				I. Ilias and K. Pacak Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 479 - 491. [Full Text] [PDF]

				I. Ilias, J. Yu, J. A. Carrasquillo, C. C. Chen, G. Eisenhofer, M. Whatley, B. McElroy, and K. Pacak Superiority of 6-[18F]-Fluorodopamine Positron Emission Tomography Versus [131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4083 - 4087. [Abstract] [Full Text] [PDF]

				A.-M. O'Carroll Localization of Messenger Ribonucleic Acids for Somatostatin Receptor Subtypes (sstr1-5) in the Rat Adrenal Gland J. Histochem. Cytochem., January 1, 2003; 51(1): 55 - 60. [Abstract] [Full Text] [PDF]

				A. M. Isidori, G. Kaltsas, V. Frajese, B. Kola, R. A. F. Whitelocke, P. N. Plowman, K. E. Britton, J. P. Monson, A. B. Grossman, and G. M. Besser Ocular Metastases Secondary to Carcinoid Tumors: The Utility of Imaging with [123I]Meta-Iodobenzylguanidine and [111In]DTPA Pentetreotide J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1627 - 1633. [Abstract] [Full Text] [PDF]